Skip to main content

Table 1 Demographic information for the PWS and AS groups

From: Exploring autism symptoms in an Australian cohort of patients with Prader-Willi and Angelman syndromes

  PWS AS
Medication use
 Growth hormone 68.0% 0%
 Anticonvulsant 8.0% 73.7%
Genetic subtype
 Deletion 24.0% 47.4%
 UPD 64.0% 15.8%
 Imprinting centre defect 8.0% 0%
 Abnormal methylationa 4.0% 5.2%
UBE3A mutation NA 31.6%
  1. aMethylation analysis confirmed PWS or AS diagnosis, but further analysis to confirm specific subtypes had not been undertaken